Nab-paclitaxel plus gemcitabine regimen for pancreatic cancer

Hospital Pharmacy

Volumn 49, Issue 1, 2014, Pages 18-22

  Porter, Courtney ^a   Waddell, J Aubrey ^b   Solimando Jr , Dominic ^c  

^a BLOUNT MEMORIAL HOSPITAL   (United States)

^b Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; DOLASETRON MESILATE; GEMCITABINE; GRANISETRON; HEMOPOIETIC GROWTH FACTOR; METOCLOPRAMIDE; ONDANSETRON; PACLITAXEL; PALONOSETRON; PROCHLORPERAZINE; PROMETHAZINE;

ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG SYNTHESIS; FATIGUE; HUMAN; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PANCREAS CANCER; PNEUMONIA; SEPSIS; VOMITING;

EID: 84892161155     PISSN: 00185787     EISSN: 19451253     Source Type: Journal    
DOI: 10.1310/hpj4901-18     Document Type: Article

References (23)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - Pancreatic Adenocarcinoma. V.1.2013. http://www.nccn.org. Accessed October 11, 2013.
2. Zhang D, Wang D, Wang Z, et al. Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2013;71:1065-1072.
3. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I/II trial. J Clin Oncol. 2011;29(34):4548-4554.
4. Von Hoff DD, Ervin TJ, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691- 1703.
5. Abraxane [product labeling]. Summit, NJ: Celgene Corporation; 2013. http://www.abraxane.com/downloads/Abraxane-PrescribingInformation.pdf. Accessed October 18, 2013.
6. Paik P, James L, Riely G, et al. A phase II study of weekly albumin-bound paclitaxel (Abraxane) given as a two-hour infusion. Cancer Chemother Pharmacol. 2011;68(5):1331-1337.
7. Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003;21(18): 3402-3408.
8. NCCN Clinical Practice Guidelines in Oncology for Antiemesis. V.1.2014. National Comprehensive Cancer Network Web site. www.nccn.org. Accessed October 18, 2013.
9. Multinational Association for Supportive Care in Cancer. Antiemetic Guidelines. 2011. http://data.memberclicks.com/site/mascc/MASCC-Guidelines- English-2011.pdf. Accessed October 31, 2013.
10. American Society of Clinical Oncology. Antiemetics: ASCO Clinical Practice Guideline Update. http://www.asco.org/institute-quality/antiemetics- asco-clinical-practice-guidelineupdate. Accessed October 31, 2013.
11. Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005;23(6):1289-1294.
12. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15(1):103-109.
13. Terrey JP, Aapro MS. The activity of granisetron in patients who had previously failed ondansetronantiemetic therapy. Eur J Clin Res. 1996;8:281-288.
14. Carmichael J, Keizer HJ, Cupissol D, Milliez J, Scheidel P, Schindler AE. Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs. 1998; 9(5):381-385.
15. de Wit R, de Boer AC, vd Linden GH, Stoter G, Sparreboom A, Verweij J. Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer. 2001;85(8):1099-1101.
16. Smith IE. A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol. 1993; 119(6):350-354.
17. Soukop M. A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer. 1994;2(3):177-183.
18. NCCN Clinical Practice Guidelines in Oncology for Myeloid Growth Factors. V.2.2013. National Comprehensive Cancer Network Web site. www.nccn.org. Accessed October 16, 2013.
19. Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev. 1995;21(1):33-64.
20. Delaloge S, Llombart A, Di Palma M, et al. Gemcitabine in patients with solid tumors and renal impairment. Am J Clin Oncol. 2004;27(3):289-293.
21. Boyiadzis MM, Lebowitz PF, Frame JN, Fojo T. Hematology- Oncology Therapy. New York: McGraw-Hill; 2007:570-578.
22. Biakhov MY, Kononova GV, Iglesias J, et al. nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: A pilot study. Expert Opin Drug Saf. 2010;9(4): 515-523.
23. Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol. 2006;33(1):50-67.